Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids
- PMID: 16442037
- DOI: 10.1111/j.1524-4725.2006.32036.x
Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids
Abstract
Background: Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox Cosmetic, Allergan Inc., Irvine, CA, USA) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
Objective: To compare the efficacy and safety of botulinum toxin type A with placebo and three topical products in treating moderate-to-severe glabellar lines.
Methods: This single-center, randomized, investigator-blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin-SD (Klein-Becker USA, Salt Lake City, UT, USA), DDF Wrinkle Relax (Doctor's Dermatologic Formula, HDS Cosmetics, Inc., Yonkers, NY, USA), and HydroDerm (Hydroderm, Beverly Hills, CA, USA). Baseline and follow-up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS), subjects' global assessment of overall change in appearance, subject ratings of glabellar-related self-perception pre- and post-treatment, and satisfaction with treatment.
Results: Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p<.001). Statistically significant improvements were similarly observed for subject-reported outcomes and satisfaction with botulinum toxin type A treatment, whereas treatment with any of the three topical creams did not result in a significant difference from placebo. Three adverse events occurred in three subjects who received StriVectin-SD.
Conclusion: Botulinum toxin type A provided significantly greater efficacy and patient satisfaction in the treatment of glabellar frown lines than StriVectin-SD, Wrinkle Relax, and HydroDerm, and in the objective measurements used, none of the topical preparations were better than botulinum toxin.
Comment in
-
Letter: Benzyl alcohol preserved saline used to dilute injectables poses a risk of contact dermatitis in fragrance-sensitive patients.Dermatol Surg. 2007 Nov;33(11):1396-7. doi: 10.1111/j.1524-4725.2007.33300.x. Dermatol Surg. 2007. PMID: 17958600 No abstract available.
Similar articles
-
Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.Dermatol Surg. 2005 Oct;31(10):1297-303. doi: 10.1111/j.1524-4725.2005.31206. Dermatol Surg. 2005. PMID: 16188182 Clinical Trial.
-
Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.J Cosmet Dermatol. 2013 Dec;12(4):261-6. doi: 10.1111/jocd.12059. J Cosmet Dermatol. 2013. PMID: 24305424 Clinical Trial.
-
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.Plast Reconstr Surg. 2003 Sep 15;112(4):1089-98. doi: 10.1097/01.PRS.0000076504.79727.62. Plast Reconstr Surg. 2003. PMID: 12973229 Clinical Trial.
-
Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.Am J Clin Dermatol. 2003;4(10):709-25. doi: 10.2165/00128071-200304100-00005. Am J Clin Dermatol. 2003. PMID: 14507232 Review.
-
Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.Am J Clin Dermatol. 2011 Dec 1;12(6):377-88. doi: 10.2165/11592100-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21877763 Review.
Cited by
-
An Evaluation of Use of Botulinum Toxin Type A in the Management of Dynamic Forehead Wrinkles - A Clinical Study.J Clin Diagn Res. 2016 Oct;10(10):ZC127-ZC131. doi: 10.7860/JCDR/2016/21904.8695. Epub 2016 Oct 1. J Clin Diagn Res. 2016. PMID: 27891474 Free PMC article.
-
Cosmeceuticals: the new medicine of beauty.Mo Med. 2011 Jan-Feb;108(1):60-3. Mo Med. 2011. PMID: 21462614 Free PMC article. Review.
-
Proactive Aesthetic Strategies: Evaluating the Preventive Role of Botulinum Toxin in Facial Aging.Muscles. 2025 Aug 13;4(3):31. doi: 10.3390/muscles4030031. Muscles. 2025. PMID: 40843918 Free PMC article. Review.
-
Topical management of striae distensae (stretch marks): prevention and therapy of striae rubrae and albae.J Eur Acad Dermatol Venereol. 2016 Feb;30(2):211-22. doi: 10.1111/jdv.13223. Epub 2015 Oct 20. J Eur Acad Dermatol Venereol. 2016. PMID: 26486318 Free PMC article. Review.
-
Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact.Medicine (Baltimore). 2023 Jul 1;102(S1):e32375. doi: 10.1097/MD.0000000000032375. Medicine (Baltimore). 2023. PMID: 37499082 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical